Chelsea Anderson

206-389-4516
canderson@fenwick.com
Counsel
Corporate

Chelsea
Anderson

Chelsea
Anderson

Chelsea
Anderson

Counsel
Corporate

Chelsea advises on a variety of corporate matters, working with clients in the technology and life sciences industries. Chelsea has represented public and private companies as well as investors in a broad range of corporate securities transactions, including initial public offerings, PIPEs, follow-on and secondary offerings, at-the-market offerings and mergers and acquisitions. She also advises clients regarding securities law compliance and disclosure matters, corporate governance, Exchange Act reporting obligations and regulatory and stock exchange requirements.

Before joining Fenwick, Chelsea served as a corporate securities associate at a leading Seattle-based law firm. Following law school, Chelsea served as a law clerk to the Honorable Ronald M. Gould of the U.S. Court of Appeals for the Ninth Circuit.

The Best Lawyers in America named Chelsea to its “Ones to Watch” list for Corporate Law in 2024.

  • Achieve Life Sciences
  • Attovia Therapeutics
  • Bill.com
  • Coinbase
  • Databricks
  • Day One Biopharmaceuticals
  • Escient Pharmaceuticals
  • Gritstone Bio
  • Icertis
  • Included Health
  • Maze Therapeutics
  • Model N
  • Nautilus
  • Neoleukin Therapeutics
  • Nurix Therapeutics
  • Passage Bio
  • Redfin
  • Scribd
  • Smartsheet
  • Veracyte
  • Wealthfront

  • Achieve Life Sciences
  • Attovia Therapeutics
  • Bill.com
  • Coinbase
  • Databricks
  • Day One Biopharmaceuticals
  • Escient Pharmaceuticals
  • Gritstone Bio
  • Icertis
  • Included Health
  • Maze Therapeutics
  • Model N
  • Nautilus
  • Neoleukin Therapeutics
  • Nurix Therapeutics
  • Passage Bio
  • Redfin
  • Scribd
  • Smartsheet
  • Veracyte
  • Wealthfront

  • Smartsheet in its $8.4B acquisition by Blackstone and Vista Equity Partners
  • Alpine Immune Sciences in its $4.9B acquisition by Vertex Pharmaceuticals
  • Dice Therapeutics in its $2.4B acquisition by Eli Lilly
  • Model N in its $1.25B acquisition by Vista Equity Partners
  • Neoleukin Therapeutics in its reverse merger with Neurogene
  • Aceragen in its merger with Idera Pharmaceuticals

  • Smartsheet in its $8.4B acquisition by Blackstone and Vista Equity Partners
  • Alpine Immune Sciences in its $4.9B acquisition by Vertex Pharmaceuticals
  • Dice Therapeutics in its $2.4B acquisition by Eli Lilly
  • Model N in its $1.25B acquisition by Vista Equity Partners
  • Neoleukin Therapeutics in its reverse merger with Neurogene
  • Aceragen in its merger with Idera Pharmaceuticals

Recognition Recognition Recognition

Recognition Recognition Recognition

Recognition
The Best Lawyers in America

2024

Named Chelsea to its Ones to Watch list for Corporate Law

Recognition
The Best Lawyers in America

2024

Named Chelsea to its Ones to Watch list for Corporate Law